This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OvaScience Provides Update On Pipeline Advancements And Commercial Plans; New Potential Fertility Treatment OvaPrime℠ To Launch In 2015

OvaScience SM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg precursor cell (EggPC SM) technology platform. OvaScience expects to commercialize AUGMENT SM in international in vitro fertilization (IVF) clinics in 2014 and to launch its newest potential fertility treatment, OvaPrime SM, in 2015.

OvaScience plans to introduce its AUGMENT Centers of Excellence (ACE) access program into international IVF clinics for physicians to gain experience using AUGMENT and to generate data. In 2014, the Company expects to establish ACE clinics in at least four international regions, which the Company anticipates will result in 40 to 60 AUGMENT cycles this year. By year end, OvaScience expects to transition these ACE clinics to commercial centers.

“Accessing the international fertility markets represents the largest commercial opportunity for OvaScience,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “ACE will provide key opinion leaders in IVF clinics with experience using AUGMENT and enable us to gather further data. We look forward to making AUGMENT available to patients in these regions of high unmet need.”

OvaPrime SM, the latest addition to OvaScience’s pipeline, is designed to boost a woman’s egg reserve using her own EggPCs. OvaScience will conduct further studies and continue product optimization in 2014 in anticipation of a commercial launch of OvaPrime in 2015.

Recently, OvaScience established a collaboration with Intrexon Corporation to accelerate development of OvaTure SM, the Company’s potential next generation IVF treatment, which does not require hormone hyperstimulation. OvaScience also recently formed the OvaXon Joint Venture with Intrexon to create new applications to prevent inherited diseases for human and animal health.

“Our proprietary EggPC technology platform continues to create new fertility treatments for women, such as OvaPrime,” said Arthur Tzianabos, Ph.D., Chief Science Officer of OvaScience. “In addition, we are leveraging the platform to develop innovative approaches in other areas, including the prevention of inherited diseases.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs